Figure S5 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Key Points

• PLT012 shows significant potential in enhancing antitumor immunity against liver cancer.
• In silico analysis indicates effective targeting of metastatic diseases within liver cancer.
• Humanized CD36-blocking antibody demonstrated promising effects in preclinical settings.
• Findings could lead to improved treatment options for patients with liver cancer and metastasis.